Sanofi (SAN.PA) Delnica Cena
Sanofi Cena
V zadnjih 19 letih so prihodki Sanofi rasli 2,5 % letno in dosegli 46,72 Mrd. EUR. Dobiček na delnico je rasel 4,2 % letno v zadnjih 19 letih. Za Sanofi je čista marža 16,7 % večinoma stabilna v primerjavi s 15,9 % pred nekaj leti. Po današnji ceni je dividendna donosnost približno 5,29 %. Izplačilni delež je okoli 61 % dobička. Dividenda je rasla 5,1 % letno v zadnjih 19 letih. Konsenzna 12-mesečna ciljna cena za Sanofi je 102,00 EUR, približno nad tečaj za 37,6 %. Od 30 analitikov jih 19 priporoča nakup — skupni konsenz je Nakup.
Cena delnice Sanofi
Do teh podatkov prek Eulerpool API
100.000 zahtevkov/mes. brezplačno · brez kartice
Sanofi poslovni model in analiza delnice
Pogosto postavljena vprašanja o delnici Sanofi
The business model of Sanofi SA, a renowned pharmaceutical company, revolves around the research, development, manufacturing, and distribution of a wide range of healthcare products. Sanofi SA is committed to providing innovative solutions, convenient access to medication, and improving global health outcomes. Its diversified portfolio includes prescription drugs, vaccines, over-the-counter medicines, and health-related products across various therapeutic areas. The company consistently invests in cutting-edge research, collaborations, and mergers to advance healthcare advancements. Sanofi SA's focus on patient-centric initiatives, strategic partnerships, and global presence allows it to meet the evolving healthcare needs and make a positive impact on the lives of millions worldwide.
Sanofi SA is primarily active in the pharmaceutical and healthcare industries.
The main competitors of Sanofi SA in the market are Novartis AG, Pfizer Inc., and Merck & Co., Inc.
Sanofi SA, a leading pharmaceutical company, has a rich history and background. Established in 1973, Sanofi SA traces its origins to a merger between Sanofi and Synthélabo, two renowned French pharmaceutical companies. Over the years, Sanofi SA has expanded globally and is now headquartered in Paris, France. With a strong focus on research and development, Sanofi SA strives to deliver innovative medical solutions to improve the health and well-being of individuals worldwide. The company is involved in diverse therapeutic areas, including diabetes, vaccines, rare diseases, cardiovascular diseases, and more. Sanofi SA's commitment to excellence and patient care has solidified its position as a leading player in the pharmaceutical industry.
Sanofi SA, a leading pharmaceutical company, has achieved significant milestones throughout its history. Established in 1973, Sanofi SA has continuously strived for innovation and excellence in the healthcare industry. Some noteworthy achievements include the development of breakthrough medications, such as Plavix and Lantus, that have positively impacted global health. Sanofi SA has also made remarkable strides in areas such as diabetes management, oncology research, and vaccines. The company's commitment to research and development has led to numerous regulatory approvals and successful collaborations with other healthcare organizations. With its strong track record, Sanofi SA continues to revolutionize healthcare and improve patient outcomes globally.
Sanofi SA, a renowned pharmaceutical company, has a significant global presence. The company is primarily present in multiple countries and regions across the world. Some notable countries where Sanofi SA operates prominently include France, the United States, Germany, China, Japan, Brazil, and the United Kingdom. These regions offer Sanofi SA a vast market reach and strategic foothold, allowing the company to deliver its innovative healthcare solutions and medicines to numerous patients worldwide. With its widespread presence, Sanofi SA continues to make a positive impact on healthcare systems globally, addressing the needs of diverse populations and contributing to improved health outcomes.
Sanofi SA represents values of innovation, excellence, and integrity. As a global pharmaceutical company, Sanofi focuses on discovering, developing, and delivering healthcare solutions that enhance people's lives. The company's corporate philosophy centers around patient-centered approaches, scientific expertise, and ethical business practices. Sanofi is committed to addressing unmet medical needs, fostering a culture of diversity and inclusion, and ensuring sustainability in all aspects of its operations. With its dedication to improving global health, Sanofi SA strives to be a trusted partner and a leader in healthcare innovation.
Analitiki trenutno določajo povprečno ciljno ceno 100,14 EUR za delnico Sanofi (mediana: 102,00 EUR), kar pomeni +35,1 % glede na zadnjo ceno. Konsenz temelji na 30 ocenah.
30 analitikov trenutno ocenjuje delnico Sanofi: 19 priporoča nakup, 10 držanje in 1 prodajo. Za 2026 analitiki pričakujejo, da bo Sanofi ustvaril prihodke 48,89 Mrd. EUR in dobiček na delnico 8,59 EUR.
Delnica Sanofi (SAN.PA) je uvrščena na 15 borzah, med njimi: NASDAQ (SNYNF), London (0O59.L), SIX (Zürich) (SNW.SW), XETRA (SNW.DE), Frankfurt (SNW.F), München (SNW.MU), Stuttgart (SNW.SG), Düsseldorf (SNW.DU).
Sanofi SA is a company headquartered in Paris that manufactures pharmaceutical products for a variety of diseases and medical areas. The company was formed in 2004 from the merger of Sanofi-Synthélabo and Aventis. Sanofi has various divisions, including Vaccines, Specialty Care, Consumer Healthcare, and Generics. The Vaccines division focuses on the development and production of vaccines for the prevention of infectious diseases such as influenza, polio, and meningitis. The Specialty Care division develops and distributes medications for rare diseases such as Fabry's disease, hemophilia, and multiple sclerosis. The Consumer Healthcare division produces over-the-counter drugs, vitamins, and supplements, while the Generics division manufactures generic drugs. Some of Sanofi's most well-known products include Lovenox, Plavix, Actonel, Allegra, and Nasacort. Lovenox is an anticoagulant used for the prevention and treatment of blood clots. Plavix is an antiplatelet medication used for cardiovascular conditions such as stroke and heart attack. Actonel is a bisphosphonate used for the treatment and prevention of osteoporosis. Allegra is an antihistamine used for allergies, while Nasacort is a nasal spray used for allergy treatment. Sanofi also focuses on the development of new medications and has an extensive pipeline of drug candidates in various stages of clinical development. Some of Sanofi's emerging products include Dupilumab for the treatment of atopic dermatitis and asthma, as well as Cablivi for the treatment of thrombotic thrombocytopenic purpura. Sanofi's business model is based on the manufacturing and marketing of pharmaceutical products and vaccines. The company invests significant resources in research and development of new drugs and has a strong presence in key markets worldwide. Sanofi offers a wide range of products in various therapeutic areas and provides a variety of medications for patients with different needs. The company also works closely with regulatory authorities to ensure that its products meet the highest quality standards and meet the needs of patients. Sanofi also has partnerships with other companies in the industry to accelerate the development of new products and prevent the spread of diseases. Overall, Sanofi's business model is focused on the development and marketing of innovative pharmaceutical products and vaccines to improve the well-being of patients worldwide. The company continues to invest in research and development and strives to meet the needs of patients in the fast-paced and constantly evolving world of the healthcare industry.
pričakovane prihodki za Sanofi znašajo 48,89 Mrd. EUR. Ta vrednost temelji na trenutnih finančnih podatkih in odraža poslovno uspešnost podjetja.
pričakovane dobiček za Sanofi znaša 10,41 Mrd. EUR. Čisti dobiček odraža donosnost podjetja po odbitku vseh stroškov.
Razmerje cena-dobiček (P/E) Sanofi je trenutno 8,63. Razmerje P/E primerja trenutno ceno delnice z dobičkom na delnico in pomoči vlagateljem oceniti vrednost delnice Sanofi.
Razmerje cena-prihodki (P/S) Sanofi je trenutno 1,84. Razmerje P/S primerja tržno vrednost s celotnimi letnimi prihodki in služi kot kazalnik vrednotenja delnice Sanofi.
Eulerpool ocena kvalitete za Sanofi je 5/10.
ISIN Sanofi je FR0000120578. ISIN (International Securities Identification Number) je svetovni edinstven identifikator za vrednostne papirje.
WKN Sanofi je 920657. WKN (Wertpapierkennnummer) je šestmestna nemška oznaka za identifikacijo vrednostnih papirjev.
Ticker Sanofi je SAN.PA. Ticker simbol se uporablja za trgovanje z delnicami Sanofi na borzi.
Sanofi delnica
Sanofi Konkurenčna skupina
Sanofi Ticker
Sanofi FIGI
Vse ključne kazalnike in poglobljeno analizo Sanofi v detaljnem pregledu
Naša analiza delnic Sanofi vključuje pomembne finančne kazalnike, kot so prihodki, dobiček, razmerje cena/dobiček (P/E), razmerje cena/prihodki (P/S), EBIT ter informacije o dividendah. Prav tako preučujemo aspekte, kot so delnice, tržna kapitalizacija, dolgovi, lastniški kapital in obveznosti Sanofi. Če iščete podrobnejše informacije o teh temah, na naših podstraneh nudimo obsežne analize: